Comparison of mortality outcomes in individuals with MASLD and/or MAFLD

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, estimated to affect 25% of the global population.1 However, the term NAFLD has limitations as it relies on exclusionary criteria and does not reflect underlying pathophysiology. In 2020, Eslam et al. proposed a new term "metabolic dysfunction-associated fatty liver disease" (MAFLD) which encompasses a wide range of liver conditions associated with metabolic dysregulation to highlight the metabolic abnormalities of fatty liver disease.